The move by six major drug discovery and development organizations to codify relationships that have existed for many years signals growing frustration in academia about the dearth of venture capital funding and big pharma support for early stage therapeutic development. Launch of the Global Alliance of Leading Drug Discovery and Development Centres represents a formal effort by the global institutions to collaborate on drug discovery projects of mutual interest and to improve the translational medicine hit rate.